Browsing by Author "Ürün, Y."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Article
    Citation - Scopus: 1
    Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience From the Turkish Oncology Group Kidney Cancer Consortium (tkcc) Database
    (Elsevier Inc., 2025) Bölek, H.; Sertesen, E.; Kuzu, O.F.; Tural, D.; Sim, S.; Nahit Şendur, M.A.; Ürün, Y.
    Introduction: Despite the rapid evolution in management of metastatic renal cell carcinoma (mRCC) over the past decade, challenges remain in accessing new therapies in some parts of the world. Despite therapeutic advancements, attrition rates remain persistently high. This study aims to assess the treatment patterns and attrition rates of patients with mRCC in oncology clinics across Turkey. Patients and Methods: Patients diagnosed with mRCC between January 1, 2008, and December 31, 2022, with first-line systemic treatment data, were retrospectively evaluated using the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. Results: The final analysis included a total of 1126 patients. The percentages of patients treated in the 2nd, 3rd, 4th, and 5th lines of therapy were 62.8%, 27.4%, 8.9%, and 2.1%, respectively. The drugs that were most commonly used in the groups were tyrosine kinase inhibitors (TKIs) (52.2%) and interferon (IFN)-alpha (43.3%) for the first line, TKIs (66.3%) and immunotherapy (IO) monotherapy (25.9%) for the second line, TKI (41.4%) and mTOR inhibitors (28.8%) for the third line, TKI (44.4%) and mTOR inhibitors (29%) for the fourth line, and IO monotherapy (37.5%) and TKI (25%) for the fifth line. For the first-line treatment, the primary cause of attrition was disease progression (66.4%), followed by toxicity (16.5%), death (11.2%), and patient preference (5.9%). The primary reason for attrition across all treatment lines was disease progression. Over time, the use of TKIs in first-line treatment increased, while IFN-alpha usage declined. IOs began to be utilized in earlier lines, predominantly in second-line treatment, though use of IO-based combination therapies remains limited. Conclusion: This study underscores that despite significant progress in therapeutic options, the adoption of novel agents remains slow, and attrition rates are still high. These findings indicate a disparity in systemic therapy compared to developed countries. © 2024 Elsevier Inc.
  • Thumbnail Image
    Article
    Vaccination in Patients With Cancer: Gaps in Coverage, Barriers, and the Role of Clinician Recommendations
    (Taylor and Francis Ltd., 2026) Kayaalp, M.; Akkus, E.; Arslan, C.; Hacioglu, M.B.; Semiz, H.S.; Ürün, Y.
    Cancer patients require a tailored vaccination strategy. This study aims to assess the vaccination status of cancer patients, evaluate disease incidence and severity in vaccinated individuals, identify reasons for noncompliance with guideline-recommended vaccines, and explore vaccine hesitancy. A cross-sectional survey, including 36 multiple-choice and 6 open-ended questions, was conducted in across Turkey. A total of 506 patients participated between September 1, 2024, and December 31, 2024. Among the participants, 59% (n = 302) were receiving active treatment. At the time of diagnosis, 90.5% did not have an ongoing vaccination program. Coronavirus Disease 2019 (COVID-19) (86.2%) and influenza (22.0%) were the most frequently received vaccines before treatment.The most common reason for not being vaccinated (except for COVID-19) was the absence of a medical recommendation. Higher education levels were associated with increased vaccination rates for hepatitis B, influenza, 13-valent pneumococcal conjugate vaccine (PCV13), and 23-valent pneumococcal polysaccharide vaccine (PPSV23) (p <.01). No significant relationship was found between disease stage and vaccination rates. The most frequently reported barrier to vaccination was the absence of a medical recommendation, highlighting the pivotal role of clinician engagement in improving vaccine uptake in this vulnerable population. Although international guidelines strongly recommend routine vaccination for patients with cancer, real-world data on vaccination practices, associated barriers, and health system–level implementation in middle-income countries are scarce. To address this evidence gap, this study provides real-world data on vaccination rates, determinants, and perceived barriers among cancer patients receiving care in a Turkish oncology setting. © 2026 The Author(s). Published with license by Taylor & Francis Group, LLC.